Tegsedi Now Approved in Canada for FAP Treatment in Adults
Tegsedi (inotersen), by Akcea Therapeutics and Ionis Pharmaceuticals, has been granted approval in Canada as a treatment for stage 1 or stage 2 polyneuropathy in adults with hereditary transthyretin (hATTR) amyloidosis, also called familial amyloid polyneuropathy (FAP). This announcement comes at about the same time as Tegsedi’s…